Pathstone Holdings
APLS

Pathstone Holdings’s Apellis Pharmaceuticals APLS Stock Holding History

Pathstone Holdings’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,376
Closed -$245K – 2338
2024
Q2 		$245K Buy
6,376
+1,765
+38% +$79.9K ﹤0.01% 2049
2024
Q1 		$271K Sell
4,611
-295
-6% -$18.8K ﹤0.01% 1998
2023
Q4 		$294K Buy
+4,906
New +$249K ﹤0.01% 1842

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Pathstone Holdings's APLS Position: Q3 2024 in Review

Pathstone Holdings sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 6,376 shares — an estimated $245K sold.

Pathstone Holdings first reported a position in APLS in Q4 2023 and held it in 3 quarters. The position peaked at $294K in Q4 2023. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Pathstone Holdings reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pathstone Holdings sold 6,376 Apellis Pharmaceuticals shares in Q3 2024, an estimated $245K.
  • Pathstone Holdings first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Pathstone Holdings's Apellis Pharmaceuticals position peaked at $294K in Q4 2023.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Pathstone Holdings's 13F filing for Q3 2024, filed 7 Nov 2024.